Biotech and Breakthroughs in Immuno-Oncology (White Paper)
October 13, 2020
- Paradigm-shift in disease management with the approval of immuno-oncology agents, namely,
checkpoint inhibitors, created a major shift in how patients with cancers are treated.
- The significant clinical impact of checkpoint inhibitors led to what some have seen as a goldrush,
others as a bubble, toward clinical development of immunotherapies.
- Immuno-oncology agents have not by and large cured most patients in most cancers, hence new
immunotherapeutic agents and combinations are needed.
- Over the past 5 years, much of the BioPharma industry’s focus has been on expanding the range of
immuno-oncology agents and combinations.